EquityFlow
›
Companies
› Adaptam Therapeutics
Adaptam Therapeutics
Biotech
· ES
Terapie anticorpali first-in-class (ADC e bispecifici) contro l'evasione immunitaria dei tumori.
Funding history
Date
Round
Amount
Oct 2025
Pre Seed
Adaptam Therapeutics closed a €3 million pre-seed led by Criteria Bio Ventures for cancer immunotherapy.
$3.5M
Investors
Criteria Bio Ventures
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →